Spain Continuous Glucose Monitoring Market Size, Share, Opportunities, And Trends By Type (Real-Time CGM, Intermittently CGM), By Gender (Male, Female), By Age (Greater than 20, Less than 20), By Application (Diabetic Patients, Critical Patients), And By End User Industry (Hospitals, Diagnostic Centers and Clinics, Home care) - Forecasts From 2025 To 2030
- Published : Feb 2025
- Report Code : KSI061614943
- Pages : 105
Spain Continuous Glucose Monitoring Market Size:
Spain’s continuous glucose monitoring market to surpass US$114.025 million by 2030, growing at a 10.39% CAGR from US$69.552 million in 2025.
The Spanish CGM market is booming due to the strong prevalence of diabetes and a huge focus on glycemic control. Technological advancements, like smaller sensors and longer wear times, are also improving patient experience and driving market expansion. For instance, in February 2024, Dexcom, Inc. launched its new CGM system, Dexcom ONE+, for people with diabetes worldwide. In some countries, Dexcom ONE+ supersedes the previous generation Dexcom ONE sensor.
Moreover, the integration of CGM devices with digital health platforms facilitates data sharing, remote monitoring, and personalized diabetes management. Government reimbursement policies and intense competition among major players greatly affect market dynamics.
Virtual Real-time, Diabetes Self-Management Program (DSMES) is a Spanish-language interactive group workshop facilitated through Zoom or other virtual platforms. It is the support program acknowledged by the American Diabetes Association for adults living with type 2 diabetes.
Spain Continuous Glucose Monitoring Market Growth Drivers:
- The rising prevalence of diabetes is accelerating the adoption of continuous glucose monitoring in Spain.
As the number of people with diabetes grows, so does the demand for effective diabetes management tools. CGM devices offer valuable insights into blood glucose levels, enabling patients and healthcare providers to make informed decisions about diet, exercise, and medication.
Further, in Spain, many studies have tried to define the prevalence of diabetes at various levels. Most of them revealed prevalence rates of diabetes between 10% and 15%, showing that the set estimates have probably been surpassed. As per IDF Diabetes Atlas, in 2021 people with diabetes were 5,141.3 thousand in Spain 2021, which is anticipated to increase to 5,576.0 thousand in 2030. Amongst this, Type 1 diabetes in children and adolescents was 9.7 thousand in 2021
Spain Continuous Glucose Monitoring Market Key Segments:
- By gender, males are expected to witness significant growth in Spain's continuous glucose monitoring market.
The Spain CGM market for males is growing significantly. Several factors are contributing to this growth. For instance, the prevalence of diabetes in Spain, especially type 2, requires effective blood sugar management. This is where CGM devices come in, providing real-time data for both patients and healthcare providers.
The male population (% of total population) in Spain was at 49.1 % in 2023, as gathered from the World Bank collection of development indicators compiled from officially recognized sources.
Moreover, technological advancements within CGM have resulted in increasingly accurate, more user-friendly, and less obtrusive devices, which improve the patient experience and compliance. The improved awareness and acceptability of CGM among healthcare providers as well as among patients are further fueling the market. The table below represents some of the popular CGM products available in the Spanish market.
- By age, greater than 20 is expected to witness significant growth in Spain's continuous glucose monitoring market.
The Spanish CGM market for adults 20 years of age and older is growing substantially, driven by several factors. Leading the way is the increasing prevalence of diabetes, especially type 2, among this population. This growing diabetic population generates significant demand for CGM devices, which are essential for the proper control of blood sugar levels and, therefore, reduction in the likelihood of complications associated with diabetes. Following this, 11.8% of Spanish people aged 20 and above are anticipated to have diabetes by 2030.
- By application, diabetes patients are expected to witness significant growth in Spain's continuous glucose monitoring market.
The rising prevalence of diabetes is increasing the continuous glucose monitoring market in Spain. Wearable minimally-invasive CGM sensors are transforming diabetes care by providing continuous blood glucose (BG) concentration readings in real continuously.
An increase in the genetic predisposition for diabetes and the rising ageing population are accounting for the rising incidence of the disease. The need for diabetes devices is further fueled by the increased risk of diabetes that comes with ageing.
Further, the Spanish population's shifting dietary and lifestyle patterns are another main cause for the rise in diabetes. More sedentary lifestyles, increasing consumption of processed foods and sugary drinks are contributing to the rising prevalence of obesity and type 2 diabetes.
Spain Continuous Glucose Monitoring Market Key Developments:
- In January 2024, the MiniMed 780G system from Medtronic Diabetes, which uses the Simplera Sync sensor, received CE Mark clearance, making it the first disposable, fingerstick-free CGM in the world. Designed for users seven years of age and up, this novel device features a straightforward two-step insertion method and is scheduled for limited distribution in Europe in the spring of 2024, with a phased commercial launch to follow in the summer of the same year.
Spain Continuous Glucose Monitoring Market Scope:
| Report Metric | Details |
| Spain Continuous Glucose Monitoring Market Size in 2025 | US$69.552 million |
| Spain Continuous Glucose Monitoring Market Size in 2030 | US$114.025 million |
| Growth Rate | CAGR of 10.39% |
| Study Period | 2020 to 2030 |
| Historical Data | 2020 to 2023 |
| Base Year | 2024 |
| Forecast Period | 2025 – 2030 |
| Forecast Unit (Value) | USD Million |
| Segmentation |
|
| List of Major Companies in the Spain Continuous Glucose Monitoring Market |
|
| Customization Scope | Free report customization with purchase |
The Spain continuous glucose monitoring Market is analyzed into the following segments:
- By Type
- Real-Time CGM
- Intermittently CGM
- By Gender
- By Age
- Greater than 20
- Less than 20
- By Application
- Diabetes Patients
- Critical Patients
- By End-User
- Hospitals
- Diagnostic Center and Clinics
- Home Care
Our Best-Performing Industry Reports:
1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base and Forecast Years Timeline
1.8. Key benefits for the stakeholders
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Research Process
3. EXECUTIVE SUMMARY
3.1. Key Findings
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. The Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
4.5. Analyst View
5. SPAIN CONTINUOUS GLUCOSE MONITORING MARKET BY TYPE
5.1. Introduction
5.2. Real-Time CGM
5.3. Intermittently CGM
6. SPAIN CONTINUOUS GLUCOSE MONITORING MARKET BY GENDER
6.1. Introduction
6.2. Male
6.3. Female
7. SPAIN CONTINUOUS GLUCOSE MONITORING MARKET BY AGE
7.1. Introduction
7.2. Greater than 20
7.3. Less than 20
8. SPAIN CONTINUOUS GLUCOSE MONITORING MARKET BY APPLICATION
8.1. Introduction
8.2. Diabetes Patients
8.3. Critical Patients
9. SPAIN CONTINUOUS GLUCOSE MONITORING MARKET BY END-USER
9.1. Introduction
9.2. Hospitals
9.3. Diagnostic Center and Clinics
9.4. Home Care
10. COMPETITIVE ENVIRONMENT AND ANALYSIS
10.1. Major Players and Strategy Analysis
10.2. Market Share Analysis
10.3. Mergers, Acquisitions, Agreements, and Collaborations
10.4. Competitive Dashboard
11. COMPANY PROFILES
11.1. Dexcom, Inc.
11.2. Abbott Laboratories
11.3. Medtronic
11.4. F. Hoffmann-La Roche Ltd.
11.5. Ascensia Diabetes Care
11.6. Insulet Corporation
11.7. Tandem Diabetes Care, Inc.
11.8. DiaMonTech AG
11.9. A. Menarini Diagnostics
11.10. Insulcloud S.L.
11.11. YPSOMED
11.12. Diabeloop SA
11.13. MicroTech Medical, Inc
Dexcom, Inc.
Abbott Laboratories
Medtronic
F. Hoffmann-La Roche Ltd.
Ascensia Diabetes Care
Insulet Corporation
Tandem Diabetes Care, Inc.
DiaMonTech AG
A. Menarini Diagnostics
Insulcloud S.L.
YPSOMED
Diabeloop SA
MicroTech Medical, Inc
